# IMbrave150 (NCT03434379)

> A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03434379
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Hepatocellular
- Interventions: Atezolizumab; Bevacizumab; Sorafenib
- Enrollment: 558
- Primary outcome: Overall Survival (OS) in the Global Population
- Primary outcome: Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population
- Primary outcome: Overall Survival (OS) in the China Population
- Primary outcome: PFS-IRF Per RECIST v1.1 in the China Population

## Commentary we found

- Podcasts: 73
- YouTube: 62
- X threads: 49
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imbrave150-nct03434379

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03434379", "email": "<work email>"}; the inbox owner confirms by the emailed link.